OTC · SIGY
Healthcare · Biotechnology
$0.02
Down-$0.01 (-24.14%)
Updated Sep 12, 2026, 8:14 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 7 trading sessions · Daily adjusted prices
SIGY closed at $0.02 after 7 trading sessions, down 26.33% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $0.0242 | $0.0242 | $0.0221 | $0.0221 | 19.65K |
| Aug 31, 2026 | $0.0326 | $0.036 | $0.029 | $0.029 | 105.11K |
| Aug 27, 2026 | $0.031 | $0.031 | $0.021 | $0.031 | 34K |
| Aug 26, 2026 | $0.031 | $0.031 | $0.031 | $0.031 | 300 |
| Aug 24, 2026 | $0.021 | $0.03 | $0.021 | $0.03 | 14.12K |
| Aug 19, 2026 | $0.025 | $0.025 | $0.025 | $0.025 | 10K |
| Aug 17, 2026 | $0.03 | $0.03 | $0.03 | $0.03 | 300 |
The latest Smart Investors Daily articles mentioning SIGY.
SIGY research
Company profile and research snapshot.
SIGYN THERAPEUTICS INC
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · May 7, 2026
The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain BarrierSarasota, FL and San Diego, CA, May 07,
Yahoo · Mar 13, 2026
SAN DIEGO, CA - March 13, 2026 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB: SIGY), a developer of dialysis-like therapies to address cardiovascular disease and cancer, today released the following shareholder update au...
Yahoo · Nov 18, 2025
SAN DIEGO, CA - November 18, 2025 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB: SIGY), a developer of dialysis-like therapies to address cardiovascular disease and cancer, today disclosed that its CardioDialysis(TM) tec...
Yahoo · Nov 14, 2025
SAN DIEGO, CA - November 14, 2025 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB: SIGY), a developer of dialysis-like therapies to address cardiovascular disease and cancer, today reported financial results for the third ...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SIGY.
No results
No recent SID articles mention SIGY.
